Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Acquired by V Square Quantitative Management LLC

V Square Quantitative Management LLC lifted its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 568.6% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 90,329 shares of the company’s stock after purchasing an additional 76,819 shares during the period. V Square Quantitative Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $1,423,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its stake in Dr. Reddy’s Laboratories by 43.2% in the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock valued at $36,000 after buying an additional 137 shares in the last quarter. Van ECK Associates Corp boosted its holdings in Dr. Reddy’s Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock valued at $64,000 after purchasing an additional 322 shares in the last quarter. Lifestyle Asset Management Inc. raised its holdings in Dr. Reddy’s Laboratories by 3.2% during the third quarter. Lifestyle Asset Management Inc. now owns 13,689 shares of the company’s stock worth $1,088,000 after purchasing an additional 422 shares in the last quarter. Natixis Advisors LLC lifted its position in shares of Dr. Reddy’s Laboratories by 7.2% during the 3rd quarter. Natixis Advisors LLC now owns 10,937 shares of the company’s stock worth $869,000 after buying an additional 735 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Dr. Reddy’s Laboratories during the 3rd quarter worth approximately $60,000. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on RDY shares. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. Finally, Barclays decreased their price objective on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Stock Performance

NYSE:RDY opened at $14.02 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The firm has a market cap of $11.70 billion, a price-to-earnings ratio of 22.32 and a beta of 0.50. The firm’s fifty day moving average price is $14.75 and its 200 day moving average price is $15.32. Dr. Reddy’s Laboratories Limited has a 1-year low of $13.36 and a 1-year high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, sell-side analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.